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Abstract Vitamin D deficiency has been proposed as a
possible risk factor for developing autism spectrum disor-
der (ASD). 25-Hydroxyvitamin D3 (25(OH)D3) levels were
examined in a cross-sectional population-based study in the
Faroe Islands. The case group consisting of a total popu-
lation cohort of 40 individuals with ASD (aged
15–24 years) had significantly lower 25(OH)D3 than their
62 typically-developing siblings and their 77 parents, and
also significantly lower than 40 healthy age and gender
matched comparisons. There was a trend for males having
lower 25(OH)D3 than females. Effects of age, month/sea-
son of birth, IQ, various subcategories of ASD and Autism
Diagnostic Observation Schedule score were also investi-
gated, however, no association was found. The very low
25(OH)D3 in the ASD group suggests some underlying
pathogenic mechanism.
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Introduction
Autism spectrum disorders (ASDs) are a heterogeneous
group of complex, biologically based neurodevelopmental
disorders. There are several known risk factors including a
variety of mutated and variant genes, advanced paternal
age, exposure to toxins and medications in early develop-
ment, prematurity, and birth complications (Kolevzon et al.
2007; Gardener et al. 2009; Coleman and Gillberg 2012;
Munger et al. 2012; Cannell and Grant 2013). Recently,
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as a possible environmental risk factor for ASD (Cannell
and Grant 2013; Grant and Soles 2009; Kocˇovska´ et al.
2012a, b) due to its involvement in early neurodevelopment
(Eyles et al. 2013), the immune system (Hayes et al. 2003),
and gene regulation (Ramagopalan et al. 2010) processes.
Ergocalciferol (often called vitamin D2), a direct ana-
logue of cholecalciferol (vitamin D3), is made from
ergosterol (obtained from yeast) and has been used for food
fortification and supplements. The LC–MS/MS assay in
blood (used in this study, see below) can differentiate
between and determine levels of both 25(OH)D2 and
vitamin 25(OH)D3. The 25(OH)D2 level reflects vitamin
D2 intake from supplements and the 25(OH)D3 level
reflects the vitamin D3 intake from diet, supplements or sun
exposure. The overall result is a sum of both circulating
forms and it was this overall sum that this study has used
(Feldman et al. 2011).
Indirect support for the involvement of vitamin D in
ASD comes from ecological studies, according to which
vitamin D levels vary with season and latitude and with the
degree of skin pigmentation (Grant and Soles 2009;
Dealberto 2011). The prevalence of ASD has been sug-
gested to be raised at higher latitudes and in children of
migrant mothers with darker skin (Grant and Soles 2009;
Fernell et al. 2010; Dealberto 2011).
The end product of vitamin D metabolism is calcitriol
(1,25-dihydroxyvitamin D3 or 1,25(OH)2D3) that has now
been recognized inter alia as a neuroactive hormone that
signals via nuclear receptors (Eyles et al. 2005, 2013). It
has been shown to be required for normal brain homeo-
stasis and brain development (Garcion et al. 2002). The
last 15 years have witnessed great advances in explaining
the biochemical mechanisms of the diverse actions of
calcitriol in the brain, especially its role in early neuro-
development and in degenerative processes: (1) cell dif-
ferentiation and axonal growth; (2) stimulation of
neurotrophic factor expression (e.g., cytokines); (3) reg-
ulation of calcium signalling directly in the brain; (4)
modulation of the production of the brain-derived reactive
oxygen species; (5) stimulation of glutathione (a potent
anti-oxidant, involved in DNA synthesis and repair) and
thereby down-regulating excitotoxicity (Eyles et al. 2005,
2013; Garcion et al. 2002). Outcomes of many of these
mechanisms during neurodevelopment might be relevant
in a number of Early Symptomatic Syndromes Eliciting
Neurodevelopmental Clinical Examinations (ESSENCE)
(Gillberg 2010)—conditions that are now being linked
with deficits of this vitamin/hormone, including ASD
(Eyles et al. 2013).
To date, there have only been six clinical studies mea-
suring vitamin D levels of individuals with ASD. These
are: Humble et al. (2010) (without a comparison group);
Molloy et al. (2010) (with a problematic comparison
group); Meguid et al. (2010); Mostafa and AL-Ayadhi
(2012); De Souza Tostes et al. (2012) and Gong et al.
(2014), four of which showed significantly lower levels of
vitamin D in individuals with this diagnosis as compared to
healthy comparison group (‘‘Appendix’’). Fernell et al.
(2010) demonstrated extremely low vitamin D levels in
mothers of Somali origin living in Sweden with a child
with ASD as compared to control group of Swedish
mothers.
An apparent epidemic of vitamin D deficiency is now
being recognised (Holick 2007; Adams and Hewison
2010), and this prompted us to explore the vitamin D
levels in a general population cohort of young individuals
with ASD (aged 15–24 years) and their siblings and
parents, and in a typically-developing comparison group
in the Faroe Islands. We chose the Faroe Islands for this
study for various reasons. The islands’ location in the
North Atlantic Ocean at 62000N, and its maritime climate
(high rainfall, strong winds, an average summer temper-
ature of 9 C), negatively affect the availability of the
UVB radiation of sun rays necessary for vitamin D
metabolism. Conversely, the Faroe Islanders have a diet
rich in large oily fish containing vitamin D that could
possibly, at least in part, compensate for the lack of UVB
exposure, which in turn might mean that overall vitamin
D status in the Faroe Islands could be adequate. In
addition, many variables are unusually stable, including
socioeconomic status, education, health care, familial/
genetic history, and diet. This unique total population
study in the Faroe Islands therefore offers an ideal envi-
ronment for examining associations between vitamin D
levels and ASD.
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Methods
Study Population
Participants with ASD were recruited during a two-phase
screening process of the entire Faroe Islands population
(n = 47,962) in the relevant school age group (7–16 years,
n = 7,689) for the study of ASD prevalence in the Faroe
Islands in 2002 (Ellefsen et al. 2007) (n = 43) and 2009
(n = 24) (Kocˇovska´ et al. 2012a, b). Thus the 67 individ-
uals diagnosed with ASD represent an entire age-cohort of
individuals with ASD in the Faroe Islands and therefore the
present study represents the first ever entire population
sample of vitamin D levels in ASD population. This current
cross-sectional population-based study involved 219 indi-
viduals, all of white European origin: 40 participants with a
diagnosis of ASD (31 males/9 females), their 62 typically
developing siblings (29 brothers/33 sisters), their 77 par-
ents (40 mothers/37 fathers), and 40 healthy comparisons
(28 males/12 females).
In 2008–2009, 40 of the 67 individuals with ASD from
the general population—24 participants (56 %) from the
2002 screening phase cohort and 16 (67 %) from the
2008–2009 cohort—and their close family members agreed
to have blood drawn for analysis of various environmental
factors (informed consent was obtained either from the
individual or, if younger than 18, from the parent). The 40
participants with ASD were 15–24 years old [Mean 18.9
(SD 2.9)] at the time of blood sampling, and 31 were male.
The comparison group was matched as closely as possible
for age [Mean 18.5 (SD 2.5)], season of birth and gender.
The reasons for non-participation in blood sampling among
the ASD group (n = 27) were as follows: non-participation
in the follow-up study in 2009 of those with ASD first
diagnosed in 2002 (n = 10), participation but not willing-
ness to give blood sample (n = 14), and participation but
practical difficulties in blood drawing (n = 3). The group
of 40 with blood samples had a similar gender profile and
Autism Diagnostic Observation Schedule (ADOS) (Lord
et al. 1989) scores to those from whom blood samples were
not obtained (77/73 % and 12.5/9.4 respectively, p = 0.1.
Although some degree of genetic relatedness in the
Faroe Islands can be assumed—due to the small population
and its genetic isolate character, the prevalence of autism in
the Faroe Islands has been found to be similar to other
western nations, namely 0.56 % in 2002 (Ellefsen et al.
2007) and 0.94 % in the follow up study in 2009
(Kocˇovska´ et al. 2012a, b). The fact that in the follow up
screening process an additional 24 individuals were diag-
nosed with autism, who were originally missed, and nearly
half of these were females (n = 11), supports the findings
of other studies, suggesting that girls are often missed at a
young age and that screening and diagnostic processes
need to address this phenomenon in the future (Giarelli
2010; Kocˇovska´ et al. 2013). There is good evidence (e.g.
Kopp et al. 2010) that girls with ASD are missed or mis-
diagnosed at early ages and that, in fact, they had the
symptoms from a very early age. There is little to indicate
that girls develop ASD later than boys. There were only
two families with an index child with ASD with another
sibling also diagnosed with ASD but these siblings were
not part of our study due to the age restriction (our par-
ticipants had to be born between 1985 and 1994). During
the diagnostic process in 2009, several families had sib-
lings with some ASD traits but without an ASD diagnosis.
Thus, in this vitamin D study there were no multi-ASD
families.
Ethics
The study was approved by the Scientific Ethics Commit-
tee of the Faroe Islands.
Clinical Evaluation of Individuals with ASD
Participants with ASD were clinically examined in depth,
their family history was reported by their primary care-
giver, and they were assessed using a variety of standard-
ized structured and semi-structured instruments and tests:
the diagnostic interview for social and communication
disorders (DISCO) (Wing et al. 2002), Wechsler Intelli-
gence Scales (Wechsler 1981, 1992) and the ADOS (Lord
et al. 1989) (see below). All were clinically diagnosed
according to the International Classification of Diseases,
Tenth Edition (ICD-10) (World Health Organization 1993),
and the Diagnostic and Statistical Manual of Mental Dis-
orders, Fourth Edition (DSM-IV) (American Psychiatric
Association 1994) criteria: childhood autism/autistic dis-
order; Asperger syndrome/disorder (without application of
the age criterion); atypical autism/pervasive developmental
disorder not otherwise specified (PDDNOS). The subcate-
gories were collapsed into a broader ASD study group.
The DISCO-interview is an investigator-based struc-
tured and semi-structured instrument developed with a
view to serving as a research and clinical interview with a
collateral informant (usually one of the parents, as in the
present context) for differential diagnosis within the spec-
trum of autism and other social communication disorders
(Wing et al. 2002). The DISCO-10 was used in 2002, and
the DISCO-11 in 2009.
The difference between the tenth (DISCO-10) and the
eleventh (DISCO-11) versions of the DISCO is marginal.
Stability of DISCO-algorithm subcategory diagnoses has
been shown to be more variable than that of clinical
diagnosis but still good for AD. In terms of ‘‘any ASD’’
diagnosis, DISCO-11 diagnoses showed excellent stability
J Autism Dev Disord
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over the 7-year period from school age through early adult
life (Kocˇovska´ et al. 2013).
Wechsler intelligence scales were used age-appropri-
ately for the cognitive assessment: Wechsler Intelligence
Scale for Children (WISC-III) (Wechsler 1992) in a
majority of the cases in 2002 and Wechsler Adult Intelli-
gence Scale (WAIS-R) (Wechsler 1981) in 2009.
ADOS-assessment was performed only in 2009. The
ADOS is an instrument used for diagnosing and assessing
autism, allowing a standardised assessment of autistic
symptoms (Lord et al. 1989).
Blood Sampling and Assay of 25(OH)D3
Over a period of a year during 2008–2009, all participants had
their blood drawn (EDTA monovette) at Torshavn Hospital,
Faroe Islands, to determine the levels of 25(OH)D3. More than
three quarters of the families with an index child with autism
(78 %) had their blood drawn in summer (Jun–Aug) and
autumn (Sep–Nov). The rest of the families were blood
sampled in spring (Mar–May). No ASD participants had their
blood sample drawn during the winter months. Thus it can be
expected that the ASD group might demonstrate a certain
seasonal elevation in their levels of vitamin D. In contrast, all
healthy comparisons had their blood drawn in schools during a
relatively short period between February and April 2009. In
some participants with ASD, the blood samples were drawn at
their homes due to needle phobia and/or other behavioural/
care-taking problems.
Samples were then frozen at -80 C and stored at the
Department of Biochemistry of the Biobank of Faroes. The
long-term stability of 25(OH)D3 serum concentrations for
more than 10 years has been demonstrated under similar
storage conditions (Agborsangaya et al. 2010). The stored,
frozen whole blood samples were thawed in early 2013 and
the required amount of 0.5 mL of haemolysed full blood
separated, packed, and posted to the Department of Clinical
Biochemistry, City Hospital, Birmingham, UK, where the
laboratory analyses were performed by using the ‘‘gold-
standard’’ method—liquid chromatography–tandem mass
spectrometry (LC–MS/MS), details of which have been
described by (Schottker et al. 2012). The laboratory staff
were blind to the identity and diagnostic/comparison status
of the individuals. The assay is accredited by the Vitamin
D External Quality Assessment Scheme (DEQAS) and the
laboratory is CPA accredited (available at: http://www.
deqas.org/).
By using the haematocrit (hct) of the sample, the con-
centrations of 25(OH)D3 were calculated after measurement
of the haemolysed sample (Shea and Berg 2013) which
enabled the use of the haemolysed whole blood samples. All
samples from all participants and the entire control group
were haemolysed.
We resolved to use the same reference range as (Holick
et al. 2011), since this range has been used in several
recently published studies of vitamin D levels in patients
with autism (e.g. Humble et al. 2010; Meguid et al. 2010;
Dalga˚rd et al. 2010; De Souza Tostes et al. 2012). The
Swedish reference range for 25(OH)D3 levels awaits revi-
sion and the cut off for deficiency and insufficiency are
expected to correspond to 50 and 75 nmol/L respectively.
This scale, based on the latest research, seems plausible
and practical to adopt (Priemel et al. 2010; Heaney and
Holick 2011). The cut off for ‘severe deficiency’ (25 nmol/
L–10 ng/mL) fulfils a practical function in clinical settings
for the prescribed supplementation of vitamin D.
The reference range used in this study:
nmol/L ng/mL
Severe deficiency \25 10
Deficiency C25–\50 10–20
Insufficiency C50–\75 20–29
Sufficiency C75 30
Statistical Analyses
Statistical analysis was performed in Minitab (version
16.0) and SPSS (version 19). Continuous data are presented
as ‘mean’ and ‘standard deviation’ (SD) if normally dis-
tributed or as ‘median’ and ‘inter-quartile range’ (IQR) if
not normally distributed. All data on vitamin D levels for
all groups were not normally distributed, therefore we used
non-parametric tests. We treated the groups of individuals
with ASD and their siblings and parents as related.
The comparison group was selected to match as closely
as possible in terms of gender, season of birth and age to
give comparable groups for the statistical analysis.
Group comparisons of normally distributed data were
made using Student’s t test. For continuous data that were
not normally distributed (*all vitamin D levels in all
groups), Mann–Whitney tests and Kruskal–Wallis tests
were used when performing pairwise-comparisons and
several-group-comparisons respectively. A significance
level of 0.05 was considered significant for all analyses.
A linear model was used to correct for season of sam-
pling. The vitamin D levels were not normally distributed
(Anderson–Darling p \ 0.005) however, a log transfor-
mation of the vitamin D levels was (p = 0.525).
Chi squared test or the Mantel–Haenszel linear-by-linear
association Chi squared test for trend was used to assess
categorical variables. Pearson correlation and logistic
J Autism Dev Disord
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regression were used for analysis of the association
between vitamin 25(OH)D3 levels and certain background
variables.
Results
As there were several outliers with very high levels in all
groups apart from siblings, all the statistical analyses were
re-calculated with all outliers removed. However, we
consider inclusion of the outliers important and as the
results have remained unchanged and significant after
exclusion of all the outliers, we present the original results
including all the outliers unless specifically stated
otherwise.
25(OH)D3 Levels
The ASD group had significantly lower levels of
25(OH)D3 [median (IQR) = 24.8 (27.5) nmol/L] com-
pared to the healthy comparison group [median
(IQR) = 37.6 (32.3) nmol/L], (95 % CI 5.0–22.5),
p = 0.002 to their siblings [median (IQR) = 46.1 (28.3)
nmol/L] (95 % CI 9.4–24.8), and parents [median
(IQR) = 46.7 (36.2) nmol/L) (95 % CI 11.0–27.74],
(p \ 0.001 in both instances) (Fig. 1).
In the ASD group, 88 % were vitamin D deficient
(Fig. 2). Among their siblings, parents, and the comparison
group, the corresponding rates were 58, 58, and 65 %
respectively (p \ 0.001) (Table 1): for clarity and com-
parability of our results with several recently published
studies of vitamin D levels in patients with autism we
resolved to use the same reference ranges as (Holick et al.
2011) and we used values of nmol per litre (nmol/L).
Analysis of Season of Blood Sampling
Medians of vitamin D levels of individuals with ASD varied
according to season of the year in which they were sampled:
spring (n = 9) = 13.80 nmol/L, summer (n = 18) =
39.90 nmol/L and autumn (n = 12) = 22.95 nmol/L
(p = 0.017) reflecting a similar trend as that found in the study
of Faroese elder population (Dalga˚rd et al. 2010). Therefore, the
vitamin D data was adjusted for month of sampling in our
analysis.
Comparison of 25(OH)D3 Levels Across and Within
Gender
The trend for males having lower vitamin D levels was
observed in the ASD and sibling groups, although this
gender difference was statistically significant only in the
sibling group (p = 0.03). In the comparison and parent
groups both males and females had comparable levels
(Table 2).
Because of the variability in male:female ratio in all
groups (ASD group *3:1; sibling and parent groups *1:1
and the comparison group *2:1), a combined comparison
of vitamin D levels was also carried out for ‘males only’ in
all groups. There was a significant difference between the
groups (p = 0.001). Males with ASD had significantly
lower levels of 25(OH)D3 [median (IQR) = 24.7 (20.6)
nmol/L] compared to their brothers [median (IQR) = 34.6
(25.2) nmol/L] (p = 0.004) and fathers [median
(IQR) = 44.9 (49.8) nmol/L] (p \ 0.001) and also to the
healthy comparison males [median (IQR) = 37.4 (31.0)
nmol/L] (p = 0.002).
Comparison of 25(OH)D3 Levels in Individuals
with ASD Recruited in 2002 and 2009
As there were only 2 females diagnosed in 2002 and one of
them was ‘an outlier’ i.e. her 25(OH)D3 level was much
higher than all other participants’ at 153 nmol/L, it was not
meaningful to compare 25(OH)D3 levels across gender in
this 2002 group. In the 2009 group there was no difference
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Fig. 1 Box plots for 25(OH)D3 levels for ASD, comparison
(p = 0.002), parent (p \ 0.001) and sibling (p \ 0.001) groups,
(95 % CI) (asterisk outliers)
Fig. 2 25(OH)D3 status among ASD and comparison groups (95 %
CI, p = 0.003)
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between males [median 24.9 nmol/L (IQR = 20.3)] and
females [median 22.2 (IQR = 27.1)] (p = 0.37).
For comparison between 2002 and 2009 groups this
outlier was removed—there was no difference between the
25(OH)D3 levels of the 2002 group [median (IQR) = 24.7
(28.80) nmol/L] and the 2009 group [median(IQR) = 23.6
(24.38) nmol/L] (95 % CI 9.10–11.40) (p = 0.965).
Among the 24 participants (22 males/2 females)
recruited in 2002, 12 (50 %) had severely deficient, eight
(30 %) deficient, three (13 %) insufficient, and one
(=female) (4 %) sufficient levels of 25(OH)D3.
Among the 16 participants (9 males/7females) recruited
in 2009, nine (56 %) had severely deficient, six (38 %)
deficient, one (=female) (6 %) insufficient, and zero (0 %)
sufficient levels of 25(OH)D3.
Although the 2002 and 2009 cohorts were diagnosed at
two different time points, it should be noted that both
groups were blood sampled for vitamin D analysis during
the same period in 2008–2009.
25(OH)D3 Levels and Other Variables
There was no association between 25(OH)D3 levels and
age, IQ, subcategories of ASD or ADOS score. When
investigating ‘season of birth’ in the ASD group, those
born in the spring season (March–May) had the lowest
levels of 25(OH)D3 (median 13.8 nmol/L; p = 0.17) in
agreement with previous literature (Grant and Soles 2009).
Among the ASD group there were 13 (32.5 %) spring
births (the comparison group was matched for season of
birth therefore included the same number of spring births).
There was no correlation between 25(OH)D3 levels and
ADOS scores (p = 0.3). There was also no correlation
between 25(OH)D3 levels and the diagnosis—Asperger
syndrome (n = 18): 23.55 nmol/L (20.2); atypical autism
(n = 11): 24.7 nmol/L (29.6); autism (n = 11): 30.3 (51.8)
(p = 0.3).
Discussion
This first-ever population-based study of vitamin D in ASD
showed significantly lower levels in young adolescents/
adults with ASD than in their siblings and parents, and also
than healthy comparisons.
Our findings are consistent with those of several studies
published since 2010, although some of these had meth-
odological problems e.g., no comparison group or a prob-
lematic comparison group (Nseir et al. 2012; Kocˇovska´
et al. 2012a, b) (see ‘‘Appendix’’).
The finding that 80 % of the comparison group (which
can be considered representative of the general population
in the Faroe Islands) were in the ‘deficient/insufficient’
range and 22.5 % in the ‘severely deficient’ range
(\25 nmol/L–\10 ng/mL) that is indicative of the risk of
osteomalacia/rickets (Holick 2007), adds to the mosaic of
perceived global vitamin D deficiency in various regions of
the world. It is of note that the levels of 25(OH)D3 found in
ASD participants of the present study from the Faroe
Islands are even lower than those in other regions (see
‘‘Appendix’’). It might be that the severity of this region’s
climate and its high Northern latitude, both diminishing the
Table 1 Vitamin D status: Chi
squared test or table of
percentages of participants with
severe deficiency, deficiency,
insufficiency and sufficiency of
vitamin D (nmol/L) in the
comparison group, ASD group
and in siblings and parents of
the individuals with ASD
(Pearson Chi square = 26.730,
df = 9, p = 0.002)
Vitamin D status (nmol/L) Count % within groups Groups Total
Comparison ASD Sibling Parent
Severe deficiency \25 Count 9 21 10 18 58
% 22.5 52.5 16.1 23.4 25.5
Deficiency 25–50 Count 17 14 26 27 84
% 42.5 35.0 41.9 35.1 38.4
Insufficiency 50–75 Count 6 4 17 13 40
% 15.0 10.0 27.4 16.9 18.3
Sufficiency [75 Count 8 1 9 19 37
% 20.0 2.5 14.5 24.7 16.9
Total Count 40 40 62 77 219
% 100 100 100 100 100
Table 2 25(OH)D3 gender differences in individual groups
GROUP (n) Vitamin D level median
(nmol/L)
p (CI 95 %)
Male Female
ASD (40) 24.70 42.00 0.1 (5.6–31.1)
Comparison (40) 37.40 43.95 0.6 (12.7–23.5)
Siblings (62) 34.60 54.00 0.03 (1.2–27.3)
Parents (77) 44.90 44.45 0.9 (11.7–11.29)
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production of vitamin D by UVB rays, cannot be com-
pensated for by a diet albeit rich in large oily fish.
The only other report on vitamin D levels in the Faroe
Islands was the Faroese elder study (Dalga˚rd et al. 2010)
that found the median 25(OH)D3 concentration of 47.6
(29.8–64.8) nmol/L and a small seasonal variation in the
25(OH)D3 levels in Faroese elders, with a winter nadir of
42.6 nmol/L and a summer peak of 56.5 nmol/L (females
51.0 nmol/L; males 44.6 nmol/L). Our study found a
similarly small, insignificant seasonal variation in our ASD
group corresponding to the season of blood sampling.
Unlike in the Meguid (2010) and Gong (2014) studies
our group with the most severe diagnosis of autism had
the highest levels of vitamin D (30.30 nmol/L; p = 0.3).
This could be partially explained by the fact that 9 out of
11 individuals with autism diagnoses were blood sampled
during the summer holidays while for the two other
diagnoses there was a greater variability in season of
sampling.
The slight over-representation of spring births among
the ASD group (32.5 %) and corresponding lowest level
of vitamin D in this group (median 13.8 nmol/L;
p = 0.17) is interesting and warrants follow up. A
hypothetical explanation as to why ASD cases born in the
spring had the lowest 25(OH)D3 status in adolescence
could be that low maternal 25(OH)D3 levels led to epi-
genetic processes at the CYP24A1 gene. This gene
encodes the 24-hydroxylase that degrades calcitriol and
25(OH)D3 is subject to epigenetic regulation (methyla-
tion) during neonatal life (Novakovic et al. 2009): epi-
genetic marking and silencing of the CYP24A1 gene
could occur due to low maternal vitamin D levels pre-
venting 25(OH)D3 from reaching a level that adequately
supports CNS development. Further investigation of this
potential mechanism may be of interest. To date the
Faroese population generally has not been supplementing
with vitamin D, even in pregnancy (apart from ordinary
multivitamins with no more than 400 IU of cholecalcif-
erol or ergoclaciferol per day), and the use of solaria in
the Faroe Islands is also rare.
The trend towards lower levels of vitamin D in males in
ASD and sibling groups presented another interesting
finding. There are no acknowledged sun exposure differ-
ences between males and females among Faroese adoles-
cents. Dalga˚rd’s Faroese elder study also reported that
female gender was associated with higher 25(OH)D3 levels
(Dalga˚rd et al. 2010). Previous research has demonstrated
various gender differences in vitamin D metabolism (Spach
and Hayes 2005; Orton et al. 2006; Novakovic et al. 2009;
Feldman et al. 2011). Thus, future research is warranted, as
it would shed light on this phenomenon.
Here we only aimed at cross-sectional comparison of
vitamin D levels and we did not investigate mechanisms
involved in the differences found. It can be expected that
both diet and availability of UVB rays can influence vita-
min D levels. We did not measure calcium, parathyroid
hormone (PTH), or phosphate, which might reveal more
about the nature of the deficiency either from inadequate
sun exposure and/or inadequate dietary intake (Holick
2007). An individual’s underlying hormonal imbalance
could also play a role (Cannell and Grant 2013; Holick
2007; Feldman et al. 2011). The apparatus regulating the
hormone calcitriol (e.g. vitamin D receptors, vitamin D
binding protein, associated enzymes) is all under genetic
control and might exacerbate environmentally determined
low vitamin D status or amplify its consequences to elevate
ASD risk (Fu et al. 2009; Ahn et al. 2010; Hiraki et al.
2013). Thus future research is expected to shed light on a
possible role of genetic factors. We intend to follow up and
treat the diagnosed hypovitaminosis D among participants
with ASD and try to obtain further information on the
origin of low vitamin D status.
We have no evidence regarding the direction of cau-
sality as the blood samples of our ASD group were drawn
when they were 15–24 years of age. The low vitamin D
levels in the ASD group could be either a result of autism
impacting on a family/child’s lifestyle and/or diet (indoor
activities, selective eater, etc.) or the underlying biology of
autism altering the metabolism of vitamin D in some way
or vitamin D deficiency itself contributing to the patho-
genesis of ASD. As all groups were exposed to low levels
of sunlight, the very low 25(OH)D3 in the ASD group
suggests some other underlying pathogenic mechanism
may be involved.
Children with Williams syndrome very often have high
25(OH)D3 levels in early infancy due to a single gene
mutation, which also involves abnormal vitamin D
metabolism (Feldman et al. 2011; Stamm et al. 2001). It
would be interesting to explore whether altered vitamin D
metabolism could also be involved in the development of
autism. One of the supportive features for causality is
biological mechanism (Hennekens et al. 1987).
High ‘Body Mass Index’ (BMI) has been associated
with vitamin D deficiency (Holick 2007). We did not have
exact BMI values available for either of our comparison
groups. In our ASD group, eight participants (20 %) were
noted by diagnosing clinicians as overweight/obese. Thus,
this factor itself does not offer an exhaustive explanation
for our overall result.
An increasing body of research indicates that ASD may
be associated with a variety of complex immune dysregu-
lations, including autoimmunity, and may have a neuro-
immunecomponent (Cannell and Grant 2013; Mostafa and
AL-Ayadhi 2012; Gentile et al. 2013). Thus, future
investigation utilizing a combination of genetic, epigenetic,
and mechanistic studies of this complex interplay between
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autism, vitamin D deficiency, steroid metabolism, and
autoimmunity will be desirable.
Limitations
The main limitations of the present study were the modest
size of our sample, a lack of data regarding BMI—only
known in the some of the ASD group and lacking in all
other control groups—and a lack of information about the
participants´ habits with regards to indoor/outdoor activities
or their vitamin D supplementation. Also there was an
inconsistency of blood sampling across seasons among
various groups. These research findings require replication
with larger numbers. Because it would be challenging for
any one centre to produce data on sufficient number of
children with ASD, a multicentre international collabora-
tion would be desirable in order to achieve more conclusive
results.
Conclusions
This first-ever population study of vitamin D levels in ASD
showed significantly lower vitamin D levels in participants
with ASD (aged 15–24 years) living in the Faroe Islands,
as compared to their siblings, parents, and typically
developing comparisons. A trend of lower levels in males
compared to females in the ASD, comparison and sibling
groups was also observed.
The findings could reflect the consequences of ASD per
se impacting on a person’s lifestyle and diet or the
underlying biology of ASD impacting in some way directly
on the metabolism of vitamin D. Alternatively, the low
vitamin D levels could be an indication of life-long vitamin
D deficiency in ASD, and this hormone deficiency could, at
least theoretically, have been involved in early aberrant
development of the brain in these individuals, leading to
the development of ASD.
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